User:Mr. Ibrahem/Glasdegib

Glasdegib, sold under the brand name Daurismo, is a medication used to treat acute myeloid leukemia (AML). It is used together with cytarabine in those who cannot tolerate intensive induction chemotherapy such as those over the age of 75. It is taken by mouth.

Common side effects include low red blood cells, tiredness, bleeding, low white blood cells, pain, nausea, swelling, shortness of breath, altered taste, constipation, and rash. Other side effects include QT prolongation and infertility. Use in pregnancy may harm the baby. It is a hedgehog pathway inhibitor which blocks smoothened (SMO).

Glasdegib was approved for medical use in the United States in 2018 and Europe in 2020. In the United Kingdom it costs the NHS about £10,500 per month as of 2021. This amount in the United States is about 19,500 USD and in Canada is about 17,200 CAD.